Abstract
RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Current Gene Therapy
Title:Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy
Volume: 12 Issue: 4
Author(s): Pin-I Huang, Wen-Liang Lo, Jong-Yuh Cherng, Yueh Chien, Guang-Yuh Chiou and Shih-Hwa Chiou
Affiliation:
Keywords: Cancer gene therapy, liposomes, microRNA, non-viral delivery, nuclear localization signal, polymers, RNA interference, siRNA.
Abstract: RNA interference (RNAi) is a collection of small RNA-directed mechanisms that result in sequence-specific inhibition of gene expression. RNAi delivery has demonstrated promising efficacy in the treatment of genetic disorders in cancer. Although viral vectors are currently the most efficient systems for gene therapy, potent immunogenicity, mutagenesis, and the biohazards of viral vectors remain their major risks. Various non-viral delivery vectors have been developed to provide a safer approach for gene delivery, including polymers, peptides, liposomes, and nanoparticles. However, some concerns and challenges of these non-viral gene delivery approaches remain to be overcome. In this review, we summarize the recent progress in the development of non-viral systems delivering RNAi and the currently available preclinical and clinical data, and discuss the challenges and future directions in cancer therapy.
Export Options
About this article
Cite this article as:
Huang Pin-I, Lo Wen-Liang, Cherng Jong-Yuh, Chien Yueh, Chiou Guang-Yuh and Chiou Shih-Hwa, Non-Viral Delivery of RNA Interference Targeting Cancer Cells in Cancer Gene Therapy, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083576
DOI https://dx.doi.org/10.2174/156652312802083576 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Delicate Equilibrium between Oxidants and Antioxidants in Brain Glioma
Current Neuropharmacology Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Platinum Formulations as Anticancer Drugs Clinical and Pre-Clinical Studies
Current Topics in Medicinal Chemistry Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Meet Our Editorial Board Member
Current Pharmacogenomics and Personalized Medicine Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Poly (Lactic-co-Glycolic Acid) & Tocopheryl Polyethylene Glycol Succinate Nanoparticles for the Treatment of Different Brain Cancers
Anti-Cancer Agents in Medicinal Chemistry Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Development of Liposomes and Pseudovirions with Fusion Activity for Efficient Gene Delivery
Current Gene Therapy